GlassScriptPhysician profile
Rauf M Baba
NPI 1689677296
$25,780.03
in general payments reported to CMS, 2019-2025
48 companies · $3,599 in 2025
The $3,599 reported for 2025 was more than what 85% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,966 · 2020: $2,415 · 2021: $2,579 · 2022: $3,015 · 2023: $2,887 · 2024: $3,319 · 2025: $3,599.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,805.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,804.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $4,130.12 | 2019-2020 | |
| Lilly USA, LLC | $3,401.51 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $2,854.64 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,836.18 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Astrazeneca Pharmaceuticals LP | $1,638.91 | 2019-2023 | Farxiga |
| Abbott Laboratories | $949.46 | 2019-2025 | Freestyle Libre 3 |
| Abbvie INC. | $939.59 | 2019-2025 | Synthroid |
| Xeris Pharmaceuticals, INC. | $906.03 | 2020-2025 | Gvoke Hypopen, Recorlev |
| Mannkind Corporation | $813.28 | 2019-2023 | Afrezza |
| Amarin Pharma, INC. | $686.67 | 2019-2022 | |
| Insulet Corporation | $669.27 | 2019-2025 | Omnipod |
| Amgen INC. | $647.74 | 2020-2025 | Tepezza, Repatha, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $573.56 | 2021-2025 | |
| Corcept Therapeutics | $541.64 | 2019-2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $540.13 | 2019-2025 |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $518.05 | 2021-2025 | |
| Medtronic, INC. | $501.75 | 2021-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Medtronic Minimed, INC. | $431.30 | 2019-2020 | |
| Antares Pharma, INC. | $391.95 | 2019-2025 | Xyosted |
| Cequr Corporation | $304.33 | 2024-2025 | Cequr Simplicity |
| Sequel Med Tech, LLC | $278.58 | 2024-2025 | Twiist |
| Amneal Pharmaceuticals LLC | $154.01 | 2021-2025 | Unithroid |
| Alnylam Pharmaceuticals INC. | $124.63 | 2024 | Amvuttra |
| Ascensia Diabetes Care US INC. | $119.20 | 2024 | |
| Esperion Therapeutics, INC. | $78.46 | 2024-2025 | Nexletol |
| Dexcom, INC. | $72.29 | 2022-2024 | Dexcom G6 Transmitter |
| Ascendis Pharma Endocrinology INC | $71.10 | 2023-2025 | Yorvipath |
| Tolmar, INC. | $61.22 | 2025 | Jatenzo |
| Tandem Diabetes Care, INC. | $58.40 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Shire North American Group INC | $45.76 | 2019 | |
| Halozyme INC | $42.80 | 2023 | |
| Amphastar Pharmaceuticals, INC. | $38.42 | 2025 | |
| Boston Scientific Corporation | $37.35 | 2019 | |
| Nevro Corp. | $34.44 | 2023 | Senza |
| Azurity Pharmaceuticals, INC. | $29.98 | 2023 | Adthyza |
| Horizon Therapeutics Plc | $28.64 | 2021 | |
| Verity Pharmaceuticals INC. | $27.36 | 2025 | Tlando |
| Janssen Pharmaceuticals, INC | $26.80 | 2019 | |
| Madrigal Pharmaceuticals | $25.19 | 2025 | Rezdiffra |
| Rhythm Pharmaceuticals, INC. | $22.75 | 2025 | Imcivree |
| Ibsa Pharma INC. | $22.13 | 2023 | Tirosint, Licart |
| Neurocrine Biosciences, INC. | $18.19 | 2025 | |
| Sanofi US Services INC. | $18.10 | 2024 | |
| Currax Pharmaceuticals LLC | $15.87 | 2022 | |
| Alexion Pharmaceuticals, INC. | $14.31 | 2019 | |
| Beta Bionics, INC. | $14.10 | 2024 | Ilet Bionic Pancreas |
| Pfizer INC. | $12.53 | 2019 | |
| Eisai INC. | $11.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rauf Baba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.